NLRP3 and mucopolysaccharidosis: Even the use of pharmacological inhibitors of NLRP3-inflammasome as the small-molecule MCC950 might control neuroinflammation in MPS, blocking canonical and noncanonical NLRP3 activation in innate immunity cells, preventing NLRP3-induced ASC oligomerization, and decreasing IL-1β and IL-18 release [71].